- Hims & Hers Health, Inc. (NYSE:HIMS) is set to release its quarterly earnings with an estimated EPS of $0.12 and projected revenue of $538.4 million.
- The company’s stock price surged by 23%, closing at $35.04, following the announcement of a partnership with Novo Nordisk to sell the weight-loss drug, Wegovy.
- HIMS showcases a strong financial health with a P/E ratio of 62.84, a price-to-sales ratio of 5.27, and a debt-to-equity ratio of 0.024.
Hims & Hers Health, Inc. (NYSE:HIMS) is a telehealth company that focuses on providing personalized healthcare solutions. The company offers a range of services, including sexual health, dermatology, and mental health, which collectively generated over $1.2 billion in sales in 2024. HIMS is set to release its quarterly earnings on Monday, May 5, 2025, with Wall Street analysts estimating earnings per share (EPS) of $0.12 and projected revenue of approximately $538.4 million.
The MedTech sector, which includes companies like HIMS, is showing promising signs of recovery. As highlighted by Zacks, HIMS, along with GMED, QDRL, and HAE, is expected to surpass Q1 earnings estimates. This positive outlook is attributed to a rebound in base business activities compared to the previous year. Despite ongoing macroeconomic uncertainties, the Medical sector is demonstrating significant earnings growth, outperforming other sectors.
HIMS recently experienced a significant stock price increase of 23%, closing at $35.04 in the last trading session. This surge was driven by a higher-than-average trading volume and the company’s announcement of a new partnership to sell Novo Nordisk’s weight-loss drug, Wegovy, on its telehealth platform. This collaboration allows U.S. customers to access NovoCare Pharmacy directly through Hims & Hers Health’s online platform, offering all dose strengths of Wegovy bundled with a membership for $599 per month.
The partnership with Novo Nordisk helps to de-risk HIMS’s investment strategy, although it does not significantly shift the company’s primary focus on personalized healthcare solutions. The company had already set a target of $725 million in weight-loss sales for the year, excluding any sales from branded GLP-1 products. HIMS’s core business continues to thrive, with substantial contributions from sectors such as sexual health, dermatology, and mental health.
Financially, HIMS has a price-to-earnings (P/E) ratio of approximately 62.84, indicating that investors are willing to pay $62.84 for every dollar of earnings. The company’s price-to-sales ratio stands at about 5.27, suggesting that investors are paying $5.27 for every dollar of sales. With a debt-to-equity ratio of about 0.024, HIMS has a relatively low level of debt compared to its equity, and a current ratio of approximately 1.79, indicating a good level of liquidity to cover short-term liabilities.
